BTIG Research has recently reduced FiscalNote Holdings Inc (NOTE) stock to Neutral rating, as announced on November 15, 2023, according to Finviz. Earlier, on July 26, 2023, B. Riley Securities had ...

FREYR Battery Inc (FREY) stock saw a decline, ending the day at $2.58 which represents a decrease of $-0.12 or -4.44% from the prior close of $2.7. The stock opened at $2.71 and touched a low of $2.45 ...

BTIG analyst Julian Harrison initiated coverage with a Buy rating on VYNE Therapeutics (VYNE – Research Report) on December 30 and set a price target of $8.00. The company’s shares closed yesterday at ...

BTIG analysts initiated coverage of SunCar Tech Group (NASDAQ:SDA) with a Buy rating and a $12 price target, highlighting the ...

BTIG notes that Casago has agreed to acquire Neutral-rated Vacasa (VCSA) for $5.02/share in cash with the deal expected to close Q1-Q2 2025.

Analyst initiates coverage on cloud-based auto services provider SunCar Technology (SDA) with Buy rating, projecting 25% annualized growth.

Jonathan Krinsky, BTIG chief market technician, joins 'Closing Bell' to discuss why he's cautious on Apple and the market ...

BTIG said it would be cautious on Apple's ( NASDAQ: AAPL) stock heading into January 2025. Analyst Jonathan Krinsky said the market can continue to make upside progress into the year-end and see a new ...

On Thursday, BTIG initiated coverage on Cartesian Therapeutics, trading on NASDAQ:RNAC, with a positive outlook, assigning a Buy rating and a price target of $42.00. The stock, currently trading at ...

On Thursday, BTIG initiated coverage on Avalo Therapeutics Inc. (NASDAQ:AVTX), awarding the stock a Buy rating and setting a price target of $40.00. According to InvestingPro data, this target ...

On Wednesday, Real Brokerage Inc. (NASDAQ:REAX) was given a positive outlook by BTIG, as the firm started coverage on the company's stock with a Buy rating and a price target of $6.00. The firm ...

BTIG analyst Jeet Mukherjee initiated coverage of Arvinas (ARVN) with a Buy rating and $69 price target The company’s lead program, vepdegestrant, is a potent ER degrader for being developed for ...